Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company that develops, manufactures, markets, and distributes a portfolio of essential medicines. The company operates through three primary segments: Affordable Medicines, which includes retail generics, injectables, and biosimilars; Specialty, offering branded pharmaceuticals focused on central nervous system and endocrine disorders; and AvKARE, a distributor of pharmaceuticals for the U.S. federal government, retail, and institutional markets. Amneal operates principally in the United States, India, and Ireland. Key products include CREXONT for Parkinson’s disease and ONGENTYS for Parkinson’s disease off episodes. The company has established strategic collaborations with ApiJect Systems for advanced drug delivery, Metsera for weight loss medicines, Zambon Biotech for IPX203 in Europe, and Knight Therapeutics for IPX203 in Canada and Latin America. Founded in 2002, Amneal also maintains a development and supply agreement with Kashiv Biosciences for generic product candidates.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Drug Manufacturers - General Homepage amneal.com
Sector Healthcare IR page investors.amneal.com/investor-relations/default.aspx
Tags
generic medicines, biosimilars, specialty pharmaceuticals, injectables, central nervous system, endocrine disorders, pharmaceutical distribution, drug delivery, parkinson's disease, weight loss medicines, AvKARE, CREXONT, ONGENTYS, IPX203, ApiJect Systems, Metsera, Zambon Biotech, Knight Therapeutics, Kashiv Biosciences, BIAL
Press page investors.amneal.com/news/press-releases/default.aspx

Metrics

Valuation  
Market cap $ 7.017B
Market cap (USD) $ 7.017B
P/E 49.12
PEG —
P/BV 13.21
P/S 2.20
P/OCF 38.85
P/FCF 79.56
Dividend yield —
Turnover / mcap —
Returns  
ROE -101.8%
ROI 2.9%
ROIC 14.5%
Profit margin 2.4%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 553.3%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 48
Quality score 5.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Revenue 3.019B 2.794B 2.394B 2.212B 2.094B 1.993B 1.626B 1.663B —
Net profit 72.057M -73.876M -79.265M -270.584M 13.163M 91.059M -361.917M -19.744M —
Free cash flow 269.929M 243.175M 302.361M 18.693M 194.092M 322.556M -45.476M 167.142M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Share price 12.6 7.92 6.07 1.99 4.79 4.57 4.82 13.53 —
Price performance 12m 0.59 0.3 2.05 -0.58 0.05 -0.05 -0.64 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 351M 481M 604M 639M 663M 742M — — —
↳ YoY growth +37.0% +25.5% +5.7% +3.7% +12.0%
↳ 5y CAGR +16.1%
Borrowings, current (USD) — 89.5M 21.4M 21.5M 44.2M 30.6M 30M 34.1M 224M 6.76M
Borrowings, non-current (USD) — 1.36B 2.63B 2.61B 2.74B 2.68B 2.59B 2.39B 2.16B 2.57B
Lease liabilities (USD) — — 86M 73M 62.5M 64M 59.2M 48.9M 47M 58.8M
Cash and deposits (USD) 37.5M 0.00 213M 151M 341M 248M 26M 91.5M 111M 282M
Intangible assets (USD) — 44.6M 1.65B 1.38B 1.3B 1.17B 1.1B 890M 732M 563M
Right-of-use assets (USD) — — 85M 69.9M 58.7M 60.4M 56.1M 43.3M 42.4M 54M
Net debt (borrowings + leases - cash) (USD) — 1.28B 2.44B 2.55B 2.5B 2.53B 2.66B 2.38B 2.32B 2.35B
Cash flow detail
Operating cash flow (USD) 115M 234M 250M 1.71M 379M 242M 65.1M 346M 295M 340M
Purchases of property, plant and equipment (USD) -123M -94.8M -83.1M -47.2M -56.4M -47.7M -46.4M -43.2M -51.9M -70.1M
Purchases of intangible assets (USD) -1.85M -19.5M -14M -50.3M -4.35M -1.7M -41.8M -22.4M -14.7M -15.5M
Change in receivables (cash effect) (USD) -122M 35.3M 89.1M -133M 16.8M -23.6M -79.7M 126M -163M -121M
Change in inventories (cash effect) (USD) -42.6M -31.8M -42.9M -20.4M -114M -49M -102M -126M -131M -87M
Change in payables (cash effect) (USD) 6.27M 18.1M -55.2M -10.3M 307,000 -43.9M 110M -94.4M 235M 21.3M
Dividends paid (cash effect) (USD) -201M -375M -183M 0.00 0.00 — — — — —
Interest paid (cash effect) (USD) -50.6M -65.1M -132M -159M -130M -122M -143M -193M -264M -198M
Income taxes paid (cash effect) (USD) -4.92M -5.78M -35M -10.3M -100M 15.6M 12.6M 2.5M -15.2M -21.3M
Share-based compensation (USD) 0.00 0.00 168M 21.7M 20.8M 28.4M 31.8M 26.8M 27.8M 32M
Operating cash flow before change in receivables (USD) 238M 199M 161M 134M 362M 265M 145M 219M 458M 461M
Free cash flow (OCF - PPE - intangibles) (USD) -9.55M 120M 153M -95.7M 318M 192M -23.1M 280M 229M 254M
Income detail
Research and development expense (USD) 179M 171M 194M 188M 180M 202M 196M 164M 191M 186M
↳ 5y CAGR +2.4% +2.7% -3.3% +0.3% +0.7%
Total comprehensive income (USD) 0.00 0.00 -23.3M -353M 49.9M 27.3M -95.1M -127M -150M 26.8M
Comprehensive income to owners (USD) 0.00 0.00 -23.3M -353M 49.9M 27.3M -95.1M -127M -150M 26.8M
Reported Mar 1, 2019 Mar 1, 2019 Mar 2, 2020 Mar 2, 2020 Mar 1, 2021 Mar 1, 2022 Mar 3, 2023 Mar 14, 2024 Feb 28, 2025 Feb 27, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Amneal Reports Third Quarter 2026 Financial Results Bull 5 Bear 0 Results

November 3, 2026

– Q3 2026 Net Revenue of $863 million_; GAAP Net_ Loss of $22 million_; Diluted_ Loss per Share of $(0.06) –
– Adjusted EBITDA of $207 million_; Adjusted Diluted EPS of_ $0.26 –
– Updating 2026 Full Year Guidance –

BRIDGEWATER, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the third quarter ended September 30, 2026.

“Amneal delivered another quarter of strong, broad-based performance, enabling us to increase our 2026 guidance once more. As we prepare to enter 2027, our financial performance is accelerating driven by a number of key catalysts and new launches, including Women’s Health patches, biosimilars, injectables such as lanreotide, CREXONT®, and BREKIYA® autoinjector. The Kashiv integration is proceeding well, and we are excited about the long-term growth potential in biosimilars. With the breadth and depth of opportunities across our portfolio, we remain highly confident in Amneal’s robust growth outlook,” said Chirag and Chintu Patel, Co-Founders and Co-Chief Executive Officers of Amneal.

Third Quarter 2026 Results
Net revenue in the third quarter of 2026 was $863 million, an increase of 10% compared to $785 million in the third quarter of 2025. Affordable Medicines net revenue increased 19%, driven by biosimilars, women’s health patches, and new launches. Specialty net revenue increased 20%, driven by key branded products, including CREXONT®, BREKIYA® autoinjector, and UNITHROID®. AvKARE net revenue decreased 17%, as expected, due to a non-recurring cardiovascular product launch in the prior year.

Net loss attributable to Amneal Pharmaceuticals, Inc. was $22 million in the third quarter of 2026 compared to net income of $2 million in the third quarter of 2025 as higher revenue and gross profit were more than offset by non-recurring acquisition and integration costs, and higher tax provision.

Adjusted EBITDA in the third quarter of 2026 was $207 million, an increase of 30% compared to the third quarter of 2025, reflecting higher revenue, higher gross profit, and lower operating expenses.

Diluted loss per share in the third quarter of 2026 was $(0.06) compared to diluted income per share of $0.01 for the third quarter of 2025, due to the aforementioned factors and higher share count as a result of the Kashiv acquisition. Adjusted diluted earnings per share in the third quarter of 2026 was $0.26, an increase of 53% compared to $0.17 for the third quarter of 2025.

The Company presents GAAP and adjusted (non-GAAP) quarterly results. Please refer to the “Non-GAAP Financial Measures” section and the accompanying GAAP to non-GAAP reconciliation tables for more information.

Updating 2026 Full Year Guidance
We are increasing full year 2026 guidance for net revenue, adjusted EBITDA, and adjusted diluted EPS. The Company is also updating operating cash flow guidance, reflecting working capital, including higher inventory levels in key growth areas.

Updated Guidance Prior Guidance
Net revenue $3.15 billion - $3.25 billion $3.10 billion - $3.20 billion
Adjusted EBITDA(1) $800 million - $815 million $750 million - $780 million
Adjusted diluted EPS(2) $1.04 - $1.08 $0.96 - $1.06
Operating cash flow(3) $325 million - $375 million $350 million - $400 million
Operating cash flow, excluding discrete items(4) $350 million - $400 million $375 million - $425 million
Capital expenditures(5) ~$150 million ~$150 million
(1) Includes 100% of adjusted EBITDA from AvKARE. See also “Non-GAAP Financial Measures” below.
(2) Accounts for non-controlling interest in AvKARE. Assumes approximately 340 million weighted-average diluted shares outstanding for the year ending December 31, 2026.
(3) Represents cash provided by operating activities.
(4) Excludes discrete items such as opioid settlement costs of approximately $36 million and Kashiv acquisition and integration costs of approximately $40 million.
(5) Reflects estimated capital expenditures and deposits for future acquisition of property, plant, and equipment.

Amneal’s 2026 estimates are based on management’s current expectations, including with respect to prescription trends, pricing levels, the timing of future product launches, the costs incurred and benefits realized of restructuring activities, and our long-term strategy. The Company’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The Company cannot provide a reconciliation between non-GAAP projections and the most directly comparable measures in accordance with GAAP without unreasonable efforts because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items required for the reconciliation. The items include, but are not limited to, acquisition-related expenses, restructuring expenses and benefits, asset impairments, legal settlements, and other gains and losses. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results.

Conference Call Information
Amneal will host a conference call and live webcast at 8:30 am Eastern Time today, November 3, 2026, to discuss its results. The live webcast and presentation will be accessible through the Investor Relations section of the Company’s website at https://investors.amneal.com . To access the call through a conference line, dial 1 (833) 461-5787 (in the U.S.) with access code 304152835. A replay of the conference call will be posted shortly after the call. For a list of toll-free international numbers, visit this website: https://help.events.q4inc.com/eahc/international-dial-in-numbers .

About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Amneal was founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, and built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering more than 160 million prescriptions annually, primarily in the United States. Our Affordable Medicines segment spans retail generics, injectables, and biosimilars. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For additional information, please visit amneal.com and follow us on LinkedIn.

Cautionary Statement on Forward-Looking Statements
Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; statements regarding product launches; statements regarding our potential growth and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements.

The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events, including with respect to future market conditions, company performance and financial results, operational investments, business prospects, new strategies and growth initiatives, the competitive environment, and other events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company.

Such risks and uncertainties include, but are not limited to: risks related to integrating our acquisition (the “Kashiv Acquisition”) of Kashiv BioSciences, LLC (“Kashiv”) and realizing the anticipated benefits of the acquisition; our ability to successfully develop, license, acquire and commercialize new products on a timely basis; the competition we face in the pharmaceutical industry from brand and generic drug product companies, and the impact of that competition on our ability to set prices; our ability to obtain exclusive marketing rights for our products; the impact of illegal distribution and sale by third parties of counterfeit versions of our products or stolen products; the impact of negative market perceptions of us and the safety and quality of our products; our revenues are derived from the sales of a limited number of products, a substantial portion of which are through a limited number of customers; the continuing trend of consolidation of certain customer groups; the impact of supply chain disruption; the imposition of tariffs may adversely affect our business, results of operations and financial condition; a U.S. government shutdown could adversely impact our regulatory, operational and financial performance; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; our dependence on information technology systems and infrastructure and the potential for cybersecurity incidents, and risks associated with artificial intelligence; the impact of a prolonged business interruption within our supply chain; our ability to attract, hire and retain highly skilled personnel; risks related to federal regulation of arrangements between manufacturers of branded and generic products; our reliance on certain licenses to proprietary technologies from time to time; the significant amount of resources we expend on research and development; the risk of claims brought against us by third parties; risks related to changes in the regulatory environment, including U.S. federal and state laws related to government contracting, healthcare fraud abuse and health information privacy and security and changes in such laws; changes to Food and Drug Administration product approval requirements and review processes; the impact of healthcare reform and changes in coverage and reimbursement levels and funding by governmental authorities and other third-party payers; our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on advantageous terms; our dependence on third-party agreements for a portion of our product offerings; our potential expansion into additional international markets subjecting us to increased regulatory, economic, social and political uncertainties; the impact of global economic, political or other catastrophic events; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; our obligations under a tax receivable agreement may be significant; and the high concentration of ownership of our Class A common stock by the Amneal Group. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.

Non-GAAP Financial Measures
This release includes certain non-GAAP financial measures, including EBITDA, adjusted EBITDA, adjusted net income, adjusted diluted EPS, adjusted gross margin, adjusted operating income, net debt, gross leverage, and net leverage, which are intended as supplemental measures of the Company’s performance that are not required by or presented in accordance with GAAP.

Management uses these non-GAAP measures internally to evaluate and manage the Company’s operations and to better understand its business because they facilitate a comparative assessment of the Company’s operating performance relative to its performance based on results calculated under GAAP. These non-GAAP measures also isolate the effects of some items that vary from period to period without any correlation to core operating performance and eliminate certain charges that management believes do not reflect the Company’s operations and underlying operational performance. The compensation committee of the Company’s board of directors also uses certain of these measures to evaluate management’s performance and set its compensation. The Company believes that these non-GAAP measures also provide useful information to investors regarding certain financial and business trends relating to the Company’s financial condition and operating results and facilitate an evaluation of the financial performance of the Company and its operations on a consistent basis. Providing this information therefore allows investors to make independent assessments of the Company’s financial performance, results of operations, cash flows, net leverage and trends while viewing the information through the eyes of management.

These non-GAAP measures are subject to limitations. The non-GAAP measures presented in this release may not be comparable to similarly titled measures used by other companies because other companies may not calculate one or more in the same manner. Additionally, the non-GAAP performance measures exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements; do not reflect changes in, or cash requirements for, working capital needs; and do not reflect interest expense, or the requirements necessary to service interest or principal payments on debt. Further, our historical adjusted results are not intended to project our adjusted results of operations or financial position for any future period. To compensate for these limitations, management presents and considers these non-GAAP measures in conjunction with the Company’s GAAP results; no non-GAAP measure should be considered in isolation from or as an alternative to any measure determined in accordance with GAAP. Readers should review the reconciliations included below, and should not rely on any single financial measure to evaluate the Company’s business.

A reconciliation of each historical non-GAAP measure to the most directly comparable GAAP measure is set forth below.

October 8, 2026

BRIDGEWATER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced it will report third quarter 2026 financial results on Tuesday, November 3, 2026, before market open. The Company will host an audio webcast at 8:30 a.m. ET.

The financial results and live webcast will be available through the Investor Relations section of the Company's website at investors.amneal.com

. Individuals may register for the webcast by clicking here

. To access the call by phone, dial 1 (833) 461-5787 (U.S.) or view a list of toll-free international numbers here

. The access code is 304152835. A replay of the webcast will be available shortly after the call.

Amneal Announces FDA Approval and Launch of Lanreotide Injection Bull 5 Bear 0 Clinical/regulatory

September 18, 2026

 - Expands complex injectables portfolio with important long-acting oncology treatment

 - Immediate commercial launch supported by in-house production

BRIDGEWATER, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved its lanreotide injection, 120 mg/0.5 mL, in a sterile, single-dose prefilled syringe. The product references SOMATULINE® Depot and will launch immediately. The product received Competitive Generic Therapy (CGT) designation from the FDA.

“The approval and launch of lanreotide adds another material growth driver to our Affordable Medicines business,” said Srinivas Kone, Ph.D., Senior Vice President and Chief Scientific Officer – Affordable Medicines. “Lanreotide is a significant addition to our expanding complex injectables portfolio and reflects the strength of our integrated development and manufacturing capabilities. With dedicated, large-scale in-house manufacturing capacity, we are well positioned to reliably supply the market, broaden access to this important medicine and create meaningful long-term value for patients, providers, and shareholders.”

U.S. annual sales for SOMATULINE® Depot for the 12 months ended July 2026 were $983 million, per IQVIA®.

Lanreotide Injection is indicated for: the treatment of acromegaly, advanced gastro-enteropancreatic neuroendocrine tumors (GEP-NETs), and carcinoid syndrome. It helps control hormone levels in acromegaly, improves progression-free survival in eligible GEP-NET patients, and reduces the need for rescue therapy in patients with carcinoid syndrome.

For full prescribing information, see package insert here

.

Prompts

Amneal Pharmaceuticals, Inc. (ticker AMRX), listed in United States.

Company History

Date Change Detail
May 4, 2018 Renamed ATLAS HOLDINGS, INC. → AMNEAL PHARMACEUTICALS, INC.

ETFs Holding Amneal Pharmaceuticals, Inc.

ETF Weight in ETF Shares Market value As of
BCUS 4.46% 299,505 $ 6.499M Nov 12, 2026
ASCE 2.44% 165,979 $ 2.873M Jun 30, 2026
RSMC 1.32% 455,182 $ 9.664M Nov 17, 2026
CSMD 1.25% 310,580 $ 5.69M Jul 31, 2026
IVSS 1.18% 18,366 $ 317.915K Jun 30, 2026
EHLS 0.79% 20,035 $ 425.343K Nov 17, 2026
FSEV 0.59% 2,269 $ 39.276K Jun 30, 2026
SEIS 0.36% 120,630 $ 2.088M Jun 30, 2026
SCDS 0.24% 1,046 $ 22.092K Nov 17, 2026
MSSM 0.22% 88,865 $ 1.552M Aug 31, 2026
FESM 0.20% 684,817 $ 11.854M Jun 30, 2026
SQLV 0.20% 3,315 $ 57.383K Jun 30, 2026
RUSC 0.18% 8,209 $ 142.098K Jun 30, 2026
FSEG 0.17% 552 $ 9,555.12 Jun 30, 2026
DFAS 0.15% 2,323,830 $ 50.427M Nov 12, 2026
VFMF 0.15% 82,591 $ 1.443M Aug 31, 2026
RESM 0.13% 268 $ 4,639.08 Jun 30, 2026
PSC 0.12% 155,101 $ 2.685M Jun 30, 2026
FSML 0.11% 8,141 $ 140.921K Jun 30, 2026
IALT short -0.06% -228,107 $ -4.843M Nov 16, 2026
VFMO 0.04% 40,725 $ 711.466K Aug 31, 2026
AVMC 0.03% 7,055 $ 149.778K Nov 16, 2026
SMDX 0.03% 1,788 $ 37.959K Nov 17, 2026
DFAC 0.02% 961,419 $ 20.863M Nov 12, 2026
DXUV 0.02% 58,793 $ 1.276M Nov 12, 2026
DCOR 0.01% 236,327 $ 5.128M Nov 12, 2026
DFAU 0.01% 64,195 $ 1.393M Nov 12, 2026
DFUS 0.01% 63,366 $ 1.375M Nov 12, 2026
EBI 0.00% 30 $ 524.10 Aug 31, 2026
AVUS 0.00% 17,408 $ 369.572K Nov 16, 2026
AVLC 0.00% 3,496 $ 74.22K Nov 16, 2026
NTRL 0.00% 5,690 $ 0.00 Nov 16, 2026